September 2021 updates to the website

The website has now been updated following September's LSCMMG

The following guidelines have been added/updated:

 Vitamin D position statement- Updated 

The following medicines have been added/updated:

Adalimumab, etanercept, infliximab and abatacept  (NICE TA715) - for treating moderate rheumatoid arthritis after conventional DMARDs have failed

Ixekizumab (NICE TA718) - for treating axial spondyloarthritis

Secukinumab (NICE TA719) - for treating non-radiographic axial spondyloarthritis

The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:

Idarucizumab - adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.